Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned an average rating of “Moderate Buy” from the fourteen brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $117.00.

A number of equities analysts have commented on the stock. HC Wainwright upped their price objective on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Robert W. Baird lifted their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th. TD Cowen boosted their price target on shares of Mirum Pharmaceuticals from $115.00 to $117.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Wall Street Zen cut shares of Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Citizens Jmp reduced their price objective on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating for the company in a research report on Thursday, February 26th.

Mirum Pharmaceuticals Trading Up 1.0%

Shares of MIRM stock opened at $90.66 on Tuesday. The company has a market capitalization of $5.47 billion, a P/E ratio of -188.87 and a beta of 0.52. The company has a current ratio of 2.67, a quick ratio of 2.55 and a debt-to-equity ratio of 0.98. The business’s 50 day moving average is $95.39 and its two-hundred day moving average is $80.68. Mirum Pharmaceuticals has a twelve month low of $36.88 and a twelve month high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The company had revenue of $148.93 million for the quarter, compared to analysts’ expectations of $141.78 million. During the same quarter last year, the company earned $1.00 EPS. Mirum Pharmaceuticals’s revenue for the quarter was up 49.8% compared to the same quarter last year. Equities analysts forecast that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 3,143 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $302,325.17. Following the completion of the sale, the chief operating officer directly owned 23,286 shares of the company’s stock, valued at $2,239,880.34. This trade represents a 11.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $90.27, for a total value of $623,855.97. Following the completion of the sale, the insider owned 11,305 shares in the company, valued at approximately $1,020,502.35. This trade represents a 37.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 45,136 shares of company stock worth $4,352,029. 14.36% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Cullen Frost Bankers Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $30,000. Eurizon Capital SGR S.p.A. acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth about $32,000. CIBC Private Wealth Group LLC purchased a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $32,000. MCF Advisors LLC increased its holdings in Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at approximately $33,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.